Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress - Arix Bioscience

Close Navigation

About Strategy Team Portfolio Insights Media Contact

Overlay

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

7th September 2022

Portfolio

This post references, or is about Aura. Find out more by clicking below

Video

Cambridge, USA

Useful Tools

Download, print or share this article

Print

Print Article Email

Email

Print

Share Article